ABBVIE
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
- Conditions
- Crohn's Disease
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 62
- Registration Number
- NCT03017014
- Locations
- 🇫🇷
CHU Toulouse /ID# 153251, Toulouse CEDEX 3, Occitanie, France
🇫🇷CHU Bordeaux-Hopital Pellegrin /ID# 154620, Bordeaux, France
🇫🇷Chu de Bordeaux Hopital /Id# 157926, Bordeaux, France
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Drug: Upadacitinib (ABT-494)Drug: Placebo
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 950
- Registration Number
- NCT03006068
- Locations
- 🇺🇸
SIH Research Mumtaz, Inc /ID# 163199, Kissimmee, Florida, United States
🇦🇺Fiona Stanley Hospital /ID# 211641, Murdoch, Western Australia, Australia
🇺🇸Penn State Health Colonnade /ID# 150267, State College, Pennsylvania, United States
Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
- Conditions
- Chronic Hepatitis C Virus (HCV)
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 41
- Registration Number
- NCT03002818
- Locations
- 🇨🇭
Inselspital, Universitaetsklin, Bern, Switzerland
🇨🇭Hopital Neuchatelois, Neuchatel, Switzerland
🇨🇭Universitaetsspital Zuerich, Zurich, Switzerland
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000257
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics /ID# 157378, San Antonio, Texas, United States
🇺🇸The University of Chicago Medical Center /ID# 157375, Chicago, Illinois, United States
🇺🇸Virginia Cancer Specialists - Fairfax /ID# 157377, Fairfax, Virginia, United States
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
- Conditions
- Hidradenitis Suppurativa (HS)
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2020-06-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 17
- Registration Number
- NCT03001115
- Locations
- 🇰🇷
Kyungpook National Univ Hosp /ID# 162930, Daegu, Daegu Gwang Yeogsi, Korea, Republic of
🇰🇷Seoul National Univ Bundang ho /ID# 202254, Seongnam, Gyeonggido, Korea, Republic of
🇰🇷Ajou University Hospital /ID# 163243, Suwon-si, Gyeonggido, Korea, Republic of
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 182
- Registration Number
- NCT03000075
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 443
- Registration Number
- NCT02993523
- Locations
- 🇺🇸
Emory Midtown Infectious Disease Clinic /ID# 162534, Atlanta, Georgia, United States
🇺🇸Northwestern University Feinberg School of Medicine /ID# 201133, Chicago, Illinois, United States
🇺🇸University of Chicago Medicine /ID# 154108, Chicago, Illinois, United States
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- Drug: ABBV-927Drug: ABBV-181
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 163
- Registration Number
- NCT02988960
- Locations
- 🇨🇦
University Health Network_Princess Margaret Cancer Centre /ID# 200819, Toronto, Ontario, Canada
🇺🇸The Angeles Clinic and Researc /ID# 156324, Los Angeles, California, United States
🇺🇸The University of Chicago Medical Center /ID# 155264, Chicago, Illinois, United States
A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
- Conditions
- Ankylosing Spondylitis (AS)SpondylarthritisPsoriatic Arthritis
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 139
- Registration Number
- NCT02988674
- Locations
- 🇷🇺
Institution KhMAO-Ugra /ID# 154381, Khanty-mansiysk, Russian Federation
🇷🇺State Clinical Hospital /ID# 154373, Moscow, Russian Federation
🇷🇺Research Institute of Rheum /ID# 154378, Moscow, Russian Federation
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: risankizumab
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 145
- Registration Number
- NCT02986373